Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia.
Article in JCO Oncology Practice (September 2020)
The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.
Healthcare utilization in patients with higher-risk MDS/low-blast count AML treated with azacitidine in the ‘real-world’
Article in Leukemia & Lymphoma (February 2020)
Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain
Article in ClinicoEconomics and Outcomes Research (November 2019)